Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 1.00 |
| ▸ | CASP7 | P55210 | 15/20 | 1.00 |
| ▸ | CASP9 | P55211 | 3/20 | 1.00 |
| ▸ | CASP1 | P29466 | 6/20 | 0.82 |
| ▸ | CASP2 | P42575 | 3/20 | 0.74 |
| ▸ | CASP6 | P55212 | 3/20 | 0.74 |
| ▸ | CASP4 | P49662 | 2/20 | 0.74 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681391 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL3681388 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL30657493 | 1.00 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535575 | 0.90 | CASP3 (0.81) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535497 | 0.88 | CASP3 (0.82) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535499 | 0.88 | CASP3 (0.82) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL13925543 | 0.88 | CASP3 (0.78) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535139 | 0.87 | CASP3 (0.84) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL6535137 | 0.87 | CASP3 (0.84) | CASP3CASP7CASP9CASP1CASP2 | |
| SCHEMBL2263591 | 0.85 | CASP3 (1.00) | CASP3CASP7CASP9CASP1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001933-A4 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORP (US) | 2002-11-06 | — | — | EP | claimed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | claimed |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-7256198-B2 | Pyrimidoindolones and methods for using same | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256198-B2 | Pyrimidoindolones and methods for using same | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-7256198-B2 | Pyrimidoindolones and methods for using same | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2004078731-A1 | QUINOLINE-CARBOXYLIC ACIDS AND THE DERIVATIVES THEREOF, A FOCUSED LIBRARY | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE', LTD. (RU) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | TYMP, DPYD, TYMS | CASP3 8/4885CASP7 30/4885CASP9 47/4885 |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | CASP1, API5, CASP8 | CASP3 6/4885CASP7 8/4885CASP9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.